Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRAP-ES vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased systemic vascular resistance and reduced blood pressure. The exact molecular mechanism involves inhibition of inositol trisphosphate (IP3)-induced calcium release from the sarcoplasmic reticulum and activation of guanylate cyclase, increasing c GMP levels.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension (alone or in combination with other antihypertensives),Off-label: Heart failure (as adjunctive therapy in African American patients)
Hypertension
Oral: 25-50 mg twice daily, max 200 mg/day. IV: 10-20 mg every 4-6 hours as needed.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment (up to 20 hours in severe cases).
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Primarily hepatic via N-acetylation by N-acetyltransferase 2 (NAT2). Metabolites include hydralazine pyruvic acid hydrazone, acetylhydralazine, and others.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal (80-90% as unchanged drug); minor biliary/fecal (<10%).
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Approximately 87% bound to plasma proteins (primarily albumin).
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: 50-60% due to first-pass metabolism; Intravenous: 100%.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
GFR 10-50 m L/min: Administer every 6-8 hours. GFR <10 m L/min: Administer every 8-12 hours.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use with caution, reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Oral/IV: 0.1-0.5 mg/kg/dose every 6 hours; max initial dose 25 mg/dose.
Not established; avoid use in children.
Start at 10-25 mg twice daily; titrate slowly due to increased risk of hypotension and electrolyte disturbances.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
No FDA boxed warning for Hydralazine.
None
May cause drug-induced lupus erythematosus (especially in slow acetylators),May cause peripheral neuritis (pyridoxine deficiency),May cause tachycardia, angina, or myocardial infarction in patients with coronary artery disease,May cause hypotension and renal impairment,Monitor for signs of lupus and neuropathy
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to hydralazine,Mitral valve rheumatic heart disease,Coronary artery disease (due to reflex tachycardia)
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Take with food to reduce gastrointestinal upset. Avoid high-tyramine foods if taking concomitant MAOIs, though hydralazine itself has no direct tyramine interaction. No specific food restrictions, but limit alcohol as it may exacerbate hypotension.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: No evidence of teratogenicity in human studies; animal studies show no fetal harm. Second and third trimesters: Associated with reduced placental perfusion and fetal growth restriction; risk of neonatal hypotension, hypoglycemia, and bradycardia if used near term.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Considered compatible with breastfeeding; monitor infant for hypotension and drowsiness.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Hypertension in pregnancy may require increased dosing due to increased volume of distribution and renal clearance; start with low doses and titrate based on blood pressure response; avoid severe hypotension to maintain placental perfusion.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
Hydralazine, the active component, is a direct-acting vasodilator used for hypertension. It can cause a lupus-like syndrome, especially in slow acetylators. Monitor for tachycardia and fluid retention; consider concomitant beta-blocker and diuretic. Do not use as monotherapy for long-term management. Onset of action is rapid (15-20 min) IV, but oral bioavailability is variable (30-50%). Dose adjustments needed in renal impairment.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or lightheadedness; rise slowly from sitting or lying down.,Report any joint pain, rash, fever, or unexplained bruising/bleeding.,May cause headaches or palpitations, especially early in therapy.,Avoid sudden discontinuation to prevent rebound hypertension.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRAP-ES vs ALDORIL 25, answered by our medical review team.
HYDRAP-ES is a Antihypertensive Combination that works by Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased systemic vascular resistance and reduced blood pressure. The exact molecular mechanism involves inhibition of inositol trisphosphate (IP3)-induced calcium release from the sarcoplasmic reticulum and activation of guanylate cyclase, increasing c GMP levels.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRAP-ES and ALDORIL 25 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRAP-ES is: Oral: 25-50 mg twice daily, max 200 mg/day. IV: 10-20 mg every 4-6 hours as needed.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRAP-ES and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRAP-ES is classified as Category C. First trimester: No evidence of teratogenicity in human studies; animal studies show no fetal harm. Second and third trimesters: Associated with reduced placental perfusion and fet. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.